Non-disclosure of Known HIV Status among People Living with HIV in the Mozambique Population-Based HIV Impact Assessment (INSIDA 2021)

AIDS Behav. 2025 Jul;29(7):2054-2065. doi: 10.1007/s10461-025-04699-7. Epub 2025 Apr 10.

Abstract

Non-disclosure of known HIV-positive status is a barrier to ending HIV as a global health threat as it leads to biased measurements of HIV-treatment coverage indicators and inaccurate estimates of epidemic progress, resulting in wasted resources. Identifying and understanding factors driving non-disclosure among people living with HIV is necessary for encouraging engagement with HIV services and improving treatment coverage, resource allocation, and monitoring of HIV programs in high HIV-burden areas. This analysis assessed factors associated with non-disclosure among survey respondents who had antiretrovirals (ARVs) detected in blood specimens. HIV-positive blood specimens (n = 2,038) from the 2021 Mozambique Population-based HIV Impact Assessment were tested for the presence of ARVs. Weighted prevalence estimates of non-disclosure and select covariates are reported and factors associated with non-disclosure modeled via multivariate logistic regression. Among 1,358 respondents with ARVs detected, 14.1% did not self-report their HIV-positive status during the interview. Adjusting for socio-demographic and clinical factors, non-disclosure was more likely among younger participants aged 15-24 years (adjusted odds ratio [aOR]: 2.15, 95% Confidence Interval [CI] 1.16-4.01) and among those without knowledge of their recent sexual partner's HIV-status (aOR: 2.67, 95%CI: 1.38-5.15). Participants with an unsuppressed viral load were over six times (aOR: 6.27, 95%CI: 2.76-14.23) more likely to not disclose. Improving disclosure rates is vital to obtaining accurate HIV-treatment estimates and assessing epidemic progress. Initiatives prioritizing pre- and post-test counseling, stressing treatment literacy, emphasizing undetectable = untransmittable (U = U) campaigns, and encouraging programs that promote social support may encourage disclosure among individuals living with HIV.

La no divulgación del estado seropositivo conocido impide la monitorización de los programas de VIH y la asignación de recursos. Este análisis evaluó los factores asociados con la no divulgación entre los encuestados con antirretrovirales (ARV) detectados en muestras de sangre. Se analizaron muestras de sangre seropositivas (n = 2.038) de la Evaluación del Impacto del VIH en la Población de Mozambique 2021 para detectar la presencia de antirretrovirales. Se presentan estimaciones ponderadas de prevalencia de no divulgación y covariables, y se modelan los factores asociados por medio de regresión logística multivariante. Entre los 1.358 encuestados a los que se detectó la presencia de ARV, el 14,1% no autodeclaró su estado seropositivo. Ajustando por factores sociodemográficos y clínicos, la no divulgación fue mayor entre los encuestados de 15–24 años (aOR: 2,15; IC 95%: 1,16–4,01), los individuos que desconocían el estado serológico respecto al VIH de su pareja sexual reciente (aOR: 2,67; IC 95%: 1,38–5,15), y los participantes con carga viral no suprimida (aOR: 6,27; IC 95%: 2,76–14,23). El asesoramiento previo y posterior a la prueba, los conocimientos sobre el tratamiento, las campañas de indetectable = intransmisible, y los programas de apoyo social pueden fomentar la divulgación del estado serológico, lo que permitiría realizar evaluaciones más precisas del progreso de la epidemia.

Keywords: Antiretroviral therapy; HIV surveillance; Mozambique; Non-disclosure; PHIA; Self-reported data.

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / epidemiology
  • HIV Infections* / psychology
  • Humans
  • Male
  • Middle Aged
  • Mozambique / epidemiology
  • Prevalence
  • Self Disclosure*
  • Surveys and Questionnaires
  • Truth Disclosure*
  • Young Adult

Substances

  • Anti-HIV Agents